Find all of the sources references in the Weight First: 3 Steps to Successful Obesity Management presentation
Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD. Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342–362.
Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity 2013. 21, 2163-2171.
ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015 Sep;82(3):425-38.e5.
Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. International Journal of Obesity 2012;36(6):843-854.
Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009 Nov 7;374(9701):1606-16.
Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science 2005;307:1909-1914.
Berne C, et al. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. Diabet Med 2005;22:612–8.
Bray GA, Ryan DH. Update on obesity pharmacotherapy. Ann NY Acad Sci 2014;1311:1-13.
Change SH, Stoll CR, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 2014;149(3):275-287.
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity. Obes Res 1998 Sep;6 Suppl 2:51S-209S.
Cooper AJ, Brage S, Ekelund U, et al. Association between objectively assessed sedentary time and physical activity with metabolic risk factors among people with recently diagnosed type 2 diabetes. Diabetologia 2014 Jan;57(1):73-82.
Courcoulas AP, Christian NJ, Belle SH, et al. Weight Change and Health Outcomes at 3 Years After Bariatric Surgery Among Individuals With Severe Obesity. JAMA. 2013;310(22):2416-2425.
Després JP, Lemieux I, Prud'homme D, et al. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001;322:716-720.
DiLillo VG, Siegfried NJ, West DS. Incorporating motivational interviewing into behavioral obesity treatment. Cogn Behav Pract 2003; 10:120–130.
Eaton CB, Goodwin MA, Stange KC. Direct observation of nutrition counseling in community family practice. Am J Prev Med 2002 Oct;23(3):174-9.
Foster GD, Borradaile KE, Sanders MH, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med 2009;169:1619–1626.
Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341–52.
Garvey WT, Garber AJ, Mechanick JI, et al. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract 2014;20:977-989.
Garvey WT, Ryan DH, Bohannon NJ, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care 2014 Dec;37(12):3309-16.
Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010 Aug 21;376(9741):595-605.
Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013;36:4022–9.
Intensive Behavioral Therapy (IBT) for Obesity. U.S. Department of Health and Human Services.
Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–S138.
Kraschnewski JL, Sciamanna CN, Stuckey HL, et al. A silent response to the obesity epidemic: decline in US physician weight counseling. Med Care 2013;51:186–92.
Kushner RF. Anti-obesity drugs. Expert Opin Pharmacother 2008;9:1339-1350.
Lazo M, Solga SF, Horska A, et al. Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults with Type 2 Diabetes. Diabetes Care. 2010;33:2156–2163.
Longitudinal Assessment of Bariatric Surgery (LABS) Consortium, Flum DR, Belle SH, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361:445-54.
Ludwig DS, Friedman MI. Increasing adiposity: consequence or cause of overeating? JAMA 2014;311:2167-2168.
Medical Devices. U.S. Food and Drug Administration.
Mendieta-Zerón H, López M, Diéguez C. Gastrointestinal peptides controlling body weight homeostasis. Gen Comp Endocrinol 2008 Feb 1;155(3):481-95.
Meriwether RA, Lee JA, Lafleur AS, et al. Physical activity counseling. Am Fam Physician 2008;77(8):1129-3.
Morton GJ, Meek TH, Schwartz MW. Neurobiology of food intake in health and disease. Nat Rev Neurosci 2014 Jun;15(6):367-78.
Ogden CL, Carroll MD, Flegal KM. Prevalence of obesity in the United States. JAMA 2014;312(2):189-90.
O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 2012;20:1426–36.
Phelan S, Kanaya AM, Subak LL, et al. Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial. J Urol 2012 Mar; 187(3): 939–944.
Post RE, Mainous AG, III, Gregorie SH, et al. The influence of physician acknowledgment of patients' weight status on patient perceptions of overweight and obesity in the United States. Arch Intern Med 2011;171(4):316-321.
Potential Contributors to Obesity Infographic. The Obesity Society Infographic Task Force, November 2015. Accessed December 10, 2015.
Preventing Weight Bias. Module 2: Helping Without Harming in Clinical Practice. The Rudd Center for Food Policy and Obesity. Yale University.
Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51(1):121-129.
Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245–56.
Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 210;42:937-948.
Sumithran P, Prendergast LA, Delbridge E, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med 2011; 365:1597-1604.
Suzuki K, Jayasena CN, Bloom SR, et al. Obesity and appetite control. Exp Diabetes Res 2012;2012:824305.
Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–61.
Valassi E, Scacchi M, Cavagnini F, et al. Neuroendocrine control of food intake. Nutr Metab Cardiovasc 2008;18:158-168.
Vallis M, Piccinini-Vallis H, Sharma AM, et al. Clinical review: modified 5 As: minimal intervention for obesity counseling in primary care. Can Fam Physician 2013;59:27-31.
Wadden TA, Butryn ML, Hong PS, et al. Behavioral treatment of obesity in patients encountered in primary care settings: a systematic review. JAMA 2014 Nov 5;312(17):1779-91.
Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011 Jan;19(1):110-20.
Wing et al. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals with Type 2 Diabetes. Diabetes Care. 2011;34:1481-1486.
Wing RR, Bond DS, Gendrano IN, et al. Effect of Intensive Lifestyle Intervention on Sexual Dysfunction in Women With Type 2 Diabetes: Results From an Ancillary Look AHEAD Study. Diabetes Care. 2013;36:2937-2944.
Wing RR, Lang W, Wadden TA, et al. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes. Diabetes Care 2011;34:1481-1486.
Wing RR, Rosen RC, Fava JL, et al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med 2010 Jan;7(1 Pt 1):156-65.
Woods SC, Seeley RJ. Understanding the physiology of obesity: review of recent developments in obesity research. Int J Obes Relat Metab Disord 2002;26(suppl 4):S8-S10.
More resources are forthcoming